Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule

Cervical cancer (CC) is the second leading cause of cancer death among Filipino women. Human papillomavirus (HPV) vaccination protects against CC. Two vaccines (AS04-HPV-16/18 and 4vHPV) are approved in the Philippines; they were originally developed for a 3-dose (3D) administration and have recentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Germar, Maria Julieta, Purugganan, Carrie, Bernardino, Ma. Socorro, Cuenca, Benjamin, Chen, Y-Chen, Li, Xiao, Van Kriekinge, Georges, Lee, I-Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443386/
https://www.ncbi.nlm.nih.gov/pubmed/28075249
http://dx.doi.org/10.1080/21645515.2016.1269991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443386/
https://www.ncbi.nlm.nih.gov/pubmed/28075249
http://dx.doi.org/10.1080/21645515.2016.1269991

Ejemplares similares